{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:35:12Z","timestamp":1762508112153,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T00:00:00Z","timestamp":1589068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18am001007","JP19fk0108056","JP19fk0108104","JP19fm0108006"],"award-info":[{"award-number":["JP18am001007","JP19fk0108056","JP19fk0108104","JP19fm0108006"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grants-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports, and Technology of Japan","award":["16H06429, 16K21723, and 16H06434"],"award-info":[{"award-number":["16H06429, 16K21723, and 16H06434"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K06399"],"award-info":[{"award-number":["19K06399"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CRIP, HHSN272201400008C","CIVIC contract 75N93019C00051"],"award-info":[{"award-number":["CRIP, HHSN272201400008C","CIVIC contract 75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Ebola virus disease is a severe disease, often fatal, with a mortality rate of up to 90%. Presently, effective treatment and safe prevention options for Ebola virus disease are not available. Therefore, there is an urgent need to develop control measures to prevent or limit future Ebola virus outbreaks. Ebola virus protein-based virus-like particle (VLP) and inactivated whole virion vaccines have demonstrated efficacy in animal models, and the addition of appropriate adjuvants may provide additional benefits to these vaccines, including enhanced immune responses. In this study, we screened 24 compounds from injectable excipients approved for human use in Japan and identified six compounds that significantly enhanced the humoral response to Ebola VLP vaccine in a murine model. Our novel adjuvant candidates for Ebola VLP vaccine have already been demonstrated to be safe when administered intramuscularly or subcutaneously, and therefore, they are closer to clinical trials than adjuvants whose safety profiles are unknown.<\/jats:p>","DOI":"10.3390\/vaccines8020215","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T10:01:18Z","timestamp":1589191278000},"page":"215","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-7609","authenticated-orcid":false,"given":"Huapeng","family":"Feng","sequence":"first","affiliation":[{"name":"Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiho","family":"Nakatsu","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago Jose da Silva","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5157","authenticated-orcid":false,"given":"Seiya","family":"Yamayoshi","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"},{"name":"Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"},{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA"},{"name":"Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,10]]},"reference":[{"key":"ref_1","unstructured":"WHO (2020, January 22). Ebola Virus Disease. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ebola-virus-disease."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4167\/jbv.2011.41.3.133","article-title":"Pyrin Domain (PYD)-containing Inflammasome in Innate Immunity","volume":"41","author":"Hong","year":"2011","journal-title":"J. Bacteriol. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.chest.2019.08.2183","article-title":"Ebola Virus in the Democratic Republic of the Congo","volume":"157","author":"Wendelboe","year":"2020","journal-title":"Chest"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41564-018-0227-2","article-title":"The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses","volume":"3","author":"Goldstein","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_5","first-page":"211","article-title":"Review of Ebola Virus Infections in Domestic Animals","volume":"135","author":"Weingartl","year":"2013","journal-title":"Anim. Genom. Anim. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cid\/ciy527","article-title":"Rapid Confirmation of the Zaire Ebola Virus in the Outbreak of the Equateur Province in the Democratic Republic of Congo: Implications for Public Health Interventions","volume":"68","author":"Kingebeni","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","first-page":"548","article-title":"Ebola Viral Disease Outbreak\u2014West Africa, 2014","volume":"63","author":"Dixon","year":"2014","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1016\/j.vaccine.2017.07.054","article-title":"Vaccines against Ebola virus","volume":"36","author":"Venkatraman","year":"2018","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3389\/fimmu.2018.01803","article-title":"Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus","volume":"9","author":"Dhama","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J. Virol."},{"key":"ref_12","unstructured":"(2020, January 22). IMerck Secures FDA Authorisation for Ebola Vaccine Ervebo. Available online: http:\/\/apps.who.int\/ebola\/current-situation\/ebola-situation-report-30-march-2016)."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/14760584.2016.1187566","article-title":"Ebola virus disease candidate vaccines under evaluation in clinical trials","volume":"15","author":"Martins","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: A single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Tapia","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of Novel Adenovirus Type 26\u2013 and Modified Vaccinia Ankara\u2013Vectored Ebola Vaccines","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2008.09.020","article-title":"Protection against lethal challenge by Ebola virus-like particles produced in insect cells","volume":"383","author":"Sun","year":"2008","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2006.03.021","article-title":"Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies","volume":"351","author":"Ye","year":"2006","journal-title":"Virology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","article-title":"Virus-like particle vaccines: Immunology and formulation for clinical translation","volume":"17","author":"Donaldson","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola Virus-Like Particle\u2013Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gopal, R., and Schneemann, A. (2018). Production and Application of Insect Virus-Based VLPs. Adv. Struct. Saf. Stud., 125\u2013141.","DOI":"10.1007\/978-1-4939-7808-3_8"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/bab.1379","article-title":"Expression and characterization of hepatitis E virus-like particles and non-virus-like particles from insect cells","volume":"63","author":"Qi","year":"2015","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-27216-0_12","article-title":"Fundamentals of Baculovirus Expression and Applications","volume":"896","author":"Kost","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Arevalo, M.T., Wong, T.M., and Ross, T. (2016). Expression and Purification of Virus-like Particles for Vaccination. J. Vis. Exp.","DOI":"10.3791\/54041"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jip.2011.05.003","article-title":"A fast track influenza virus vaccine produced in insect cells","volume":"107","author":"Cox","year":"2011","journal-title":"J. Invertebr. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"An Ebola whole-virus vaccine is protective in nonhuman primates","volume":"348","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0169-409X(98)00014-3","article-title":"Targeting immune response induction with cochleate and liposome-based vaccines","volume":"32","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Feng, H., Yamashita, M., Lopes, T.J.D.S., Watanabe, T., and Kawaoka, Y. (2019). Injectable Excipients as Novel Influenza Vaccine Adjuvants. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00019"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1128\/JVI.75.11.5205-5214.2001","article-title":"Ebola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer","volume":"75","author":"Jasenosky","year":"2001","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8907","DOI":"10.1128\/JVI.73.10.8907-8912.1999","article-title":"Mutational Analysis of the Putative Fusion Domain of Ebola Virus Glycoprotein","volume":"73","author":"Ito","year":"1999","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Warfield, K.L., Dye, J.M., Wells, J.B., Unfer, R.C., Holtsberg, F.W., Shulenin, S., Vu, H., Swenson, D.L., Bavari, S., and Aman, M.J. (2015). Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118881"},{"key":"ref_35","first-page":"e51112","article-title":"Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System","volume":"10","author":"Margine","year":"2013","journal-title":"J. Vis. Exp."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1086\/520612","article-title":"Filovirus-Like Particles Produced in Insect Cells: Immunogenicity and Protection in Rodents","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Noda, T., Ebihara, H., Muramoto, Y., Fujii, K., Takada, A., Sagara, H., Kim, J.H., Kida, H., Feldmann, H., and Kawaoka, Y. (2006). Assembly and Budding of Ebolavirus. PLoS Pathog., 2.","DOI":"10.1371\/journal.ppat.0020099"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature04378","article-title":"Architecture of ribonucleoprotein complexes in influenza A virus particles","volume":"439","author":"Noda","year":"2006","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3389\/fmicb.2019.02157","article-title":"A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice","volume":"10","author":"Feng","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Feng, H., Yamashita, M., Wu, L., Lopes, T.J.S., Watanabe, T., and Kawaoka, Y. (2019). Food Additives as Novel Influenza Vaccine Adjuvants. Vaccines, 7.","DOI":"10.3390\/vaccines7040127"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1016\/j.vaccine.2014.07.079","article-title":"Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine","volume":"32","author":"Uraki","year":"2014","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/bimj.200810425","article-title":"Simultaneous Inference in General Parametric Models","volume":"50","author":"Hothorn","year":"2008","journal-title":"Biom. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1084\/jem.20011500","article-title":"Lipid raft microdomains: A gateway for compartmentalized trafficking of Ebola and Marburg viruses","volume":"195","author":"Bavari","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0168-1702(95)00080-1","article-title":"Differentiation of filoviruses by electron microscopy","volume":"39","author":"Geisbert","year":"1995","journal-title":"Virus Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-3083.2006.01862.x","article-title":"A Comparison of the Humoral and Cellular Immune Responses at Different Immunological Sites after Split Influenza Virus Vaccination of Mice","volume":"65","author":"Hauge","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0065-2776(08)60652-5","article-title":"Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T Cells","volume":"46","author":"Mosmann","year":"1989","journal-title":"Adv. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/334255a0","article-title":"Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells","volume":"334","author":"Stevens","year":"1988","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4049\/jimmunol.175.2.1184","article-title":"Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection","volume":"175","author":"Warfield","year":"2005","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","article-title":"Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections","volume":"23","author":"Swenson","year":"2005","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.vaccine.2019.05.026","article-title":"Glucopyranosyl lipid adjuvant enhances immune response to Ebola virus-like particle vaccine in mice","volume":"37","author":"Sunay","year":"2019","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent Advances of Vaccine Adjuvants for Infectious Diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Blaney, J.E., Marzi, A., Willet, M., Papaneri, A., Wirblich, C., Feldmann, F., Holbrook, M., Jahrling, P., Feldmann, H., and Schnell, M.J. (2013). Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003389"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/215\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:27:23Z","timestamp":1760174843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,10]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["vaccines8020215"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8020215","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2020,5,10]]}}}